Sun W, Wainwright C L
Department of Physiology and Pharmacology, University of Strathclyde, Glasgow, Scotland, UK.
Coron Artery Dis. 1994 Jun;5(6):541-50.
Recent studies have shown that bradykinin decreases the incidence of ischaemic arrhythmias in dogs and may also mediate the antiarrhythmic effects of preconditioning in this species. We investigated the effects of exogenously administered bradykinin on the severity of ischemic arrhythmias and the role of endogenously released bradykinin, acting on B2-receptors, in preconditioning in anaesthetized rats.
In protocol 1, male rats were subjected to a single 30 min occlusion of the left main coronary artery and received left ventricular infusions of bradykinin (30 ng to 10 micrograms/kg/min) or saline. In protocol 2, rats were pretreated with the B2-receptor antagonist HOE 140 (40 and 400 micrograms/kg intravenous bolus) 10 min before coronary artery occlusion. In protocol 3, rats were preconditioned by a 3 min coronary occlusion followed by 10 min of reperfusion before a sustained 30 min occlusion. Saline or HOE 140 was given 10 min before the preconditioning protocol. In all groups, the number and severity of ventricular arrhythmias were determined during the 30 min coronary occlusion.
In protocol 1, none of the doses of bradykinin had any significant effect on the total number of ventricular ectopic beats (1512 +/- 252 in saline-treated controls versus 1337 +/- 302 with the highest dose of bradykinin tested) or on the incidence of ventricular tachycardia or ventricular fibrillation. The two higher doses of bradykinin (1 and 10 micrograms kg/min) caused a reduction in blood pressure soon after infusion began, although this was not maintained for the duration of the experiment. In protocol 2, HOE 140, in doses that produced a sustained antagonism to the depressor response to bradykinin, had no effect on either arrhythmia count or the incidence of ventricular fibrillation in rats subjected to a single 30 min coronary occlusion. In protocol 3, a 3 min preconditioning occlusion in saline-treated rats reduced arrhythmia counts from 1046 +/- 196 in non-preconditioned rats to 76 +/- 44 in preconditioned rats, and reduced the incidences of ventricular tachycardia and ventricular fibrillation from 100 to 50% and from 75 to 7%, respectively. Neither dose of HOE 140 tested reversed these antiarrhythmic effects of preconditioning.
These results suggest that bradykinin is not protective against ischaemic arrhythmias in rats in vivo, whether given exogenously or released endogenously. Furthermore, in contrast to other species, bradykinin does not appear to play a role in the antiarrhythmic effect of ischaemic preconditioning.
近期研究表明,缓激肽可降低犬缺血性心律失常的发生率,并且可能介导该物种预处理的抗心律失常作用。我们研究了外源性给予缓激肽对缺血性心律失常严重程度的影响,以及内源性释放的缓激肽作用于B2受体在麻醉大鼠预处理中的作用。
在方案1中,雄性大鼠接受左主冠状动脉单次30分钟闭塞,并接受左心室输注缓激肽(30纳克至10微克/千克/分钟)或生理盐水。在方案2中,大鼠在冠状动脉闭塞前10分钟用B2受体拮抗剂HOE 140(40和400微克/千克静脉推注)预处理。在方案3中,大鼠在持续30分钟闭塞前,先进行3分钟冠状动脉闭塞,然后再灌注10分钟进行预处理。在预处理方案前10分钟给予生理盐水或HOE 140。在所有组中,在30分钟冠状动脉闭塞期间测定室性心律失常的数量和严重程度。
在方案1中,所有剂量的缓激肽对室性早搏总数(盐水处理对照组为1512±252,而测试的最高剂量缓激肽组为1337±302)或室性心动过速或心室颤动的发生率均无显著影响。两种较高剂量的缓激肽(1和10微克/千克/分钟)在输注开始后不久导致血压下降,尽管在实验期间未持续。在方案2中,HOE 140剂量产生对缓激肽降压反应的持续拮抗作用,对单次30分钟冠状动脉闭塞的大鼠的心律失常计数或心室颤动发生率均无影响。在方案3中,盐水处理大鼠的3分钟预处理闭塞使心律失常计数从未预处理大鼠的1046±196减少到预处理大鼠的76±44,并使室性心动过速和心室颤动的发生率分别从100%降至50%和从75%降至7%。测试的两种HOE 140剂量均未逆转预处理的这些抗心律失常作用。
这些结果表明,无论是外源性给予还是内源性释放,缓激肽在体内对大鼠缺血性心律失常均无保护作用。此外,与其他物种不同,缓激肽似乎在缺血预处理的抗心律失常作用中不起作用。